Biogen's newly approved Alzheimer's drug Aduhelm generated $2 million in revenue for Biogen in the first few weeks following its approval, the drugmaker said in its second quarter earnings report released July 22.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,